All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Piflufolastat (18F) Wins Approval in Switzerland for Detecting PSMA+ Lesions in Prostate Cancer

May 13th 2025

Switzerland has approved piflufolastat (18F) as an imaging agent to detect PSMA-positive lesions in prostate cancer.

Capecitabine/Bevacizumab Yields Antitumor Activity and a Favorable Safety Profile in Older mCRC Population

May 13th 2025

Capecitabine/bevacizumab had favorable efficacy and safety profiles among older patients with metastatic colorectal cancer.

Large Clonal Hematopoiesis Clones Are Associated With Worse Survival Outcomes in MCL

May 13th 2025

Patients with MCL and large clonal hematopoiesis clones experienced shortened PFS and OS vs those without clones.

CX-2051 Demonstrates Preliminary Activity in Heavily Pretreated Advanced Colorectal Cancer

May 13th 2025

CX-2051 elicited an overall response rate of 28% with manageable safety in heavily pretreated colorectal cancer.

THE001 Receives Orphan Drug Designation for Soft Tissue Sarcoma

May 12th 2025

THE001, a doxorubicin-encapsulating thermosensitive liposome therapy, has been granted FDA orphan drug designation for soft tissue sarcoma.

Belzutifan Displays Robust Activity in VHL-Associated RCC

May 12th 2025

Belzutifan was safe and effective in patients with von Hippel-Lindau–associated RCC and other neoplasms.

Novel Agents and Personalized Biomarkers May Propel a New Era of MDS Management

May 12th 2025

Amer Zeidan, MBBS, discusses evolutions in the myelodysplastic syndrome treatment paradigm and ongoing research seeking to improve treatment efficacy.

Roswell Park Announces Positive Progress in Clinical Trial of Novel Immunotherapy SurVaxM

May 12th 2025

The ongoing phase 2B SURVIVE clinical trial of SurVaxM in glioblastoma will continue following an interim analysis of trial data.

Frontline Disitamab Vedotin Plus Toripalimab Improves PFS and OS in HER2+ Metastatic Urothelial Carcinoma

May 12th 2025

Disitamab vedotin plus toripalimab improved PFS and OS vs chemotherapy in HER2-expressing metastatic urothelial carcinoma.

Targeted CAR T-Cell Therapies Show Early Efficacy in Solid Tumors With Focus on Mitigating Toxicity

May 12th 2025

Renier Brentjens, MD, PhD, discusses the current landscape of CAR T-cell agents in patients with solid tumors.

Allogeneic CAR T-Cell Therapy CT0596 Yields Preliminary Efficacy and Safety in R/R Myeloma

May 12th 2025

The allogeneic CAR T-cell therapy CT0596 was safe with clinical activity in relapsed/refractory multiple myeloma.

Avutometinib/Defactinib Expands Treatment Options for KRAS-Mutant Low-Grade Serous Ovarian Cancer

May 12th 2025

Bradley Monk, MD, FACOG, FACS, discusses the FDA approval of avutometinib plus defactinib for KRAS-mutated recurrent low-grade serous ovarian cancer.

ADRX-0706 Secures FDA Fast Track Designation for Advanced Squamous Cell Cervical Cancer

May 12th 2025

The FDA granted fast track designation to ADRX-0706 for locally advanced or metastatic squamous cell cervical cancer.

Patients With Progressive CLL After Zanubrutinib or Ibrutinib Therapy Often Do Not Have BTK-Mutated Disease

May 11th 2025

BTK mutations occurred at low rates in patients with CLL who had disease progression after receiving zanubrutinib or ibrutinib in the phase 3 ALPINE study.

Five Under 5: Top Oncology Videos for the Week of 5/4

May 11th 2025

The top 5 OncLive videos of the week cover insights in myelodysplastic syndrome, lung cancer, hepatocellular carcinoma, colorectal cancer, and ovarian cancer.

The OncFive: Top Oncology Articles for the Week of 5/4

May 10th 2025

A doublet is approved for KRAS-mutated ovarian cancer, T-DXd followed by THP improves pCR rates in HER2+ breast cancer, and more from OncLive.

Bendamustine/Rituximab Represents a Backbone for Therapeutic Development in MCL

May 10th 2025

Brad S. Kahl, MD, details the evaluation of induction BR plus bortezomib with rituximab/lenalidomide maintenance in mantle cell lymphoma.

Poll Results Punctuate Key Lung Cancer Abstracts Driving Intrigue Ahead of ASCO 2025

May 9th 2025

Poll results highlighted key lung cancer abstracts of interest from the upcoming ASCO Annual Meeting on OncLive’s social media.

Dostarlimab Yields High cCR Rates and Organ Preservation in Early-Stage dMMR Tumors

May 9th 2025

Neoadjuvant dostarlimab led to an 82% clinical complete response and a 92% 2-year RFS rate, supporting nonoperative management in early-stage dMMR tumors.

Patient Symptoms and Disease Features Guide Pirtobrutinib Use in R/R CLL

May 9th 2025

Nicole Lamanna, MD, discusses pirtobrutinib decision-making in the relapsed/refractory CLL setting and ongoing earlier-line research with the agent.